Brigham and Women's Hospital
Fellowship
University of Bern
Fellowship
Beth Israel Deaconess Medical Center
Residency
Beth Israel Deaconess Medical Center
Internship
Harvard Medical School
MD
Enhancing equity in academic surgery promotion practices.
Enhancing equity in academic surgery promotion practices. Surgery. 2025 Apr; 180:109023.
PMID: 39837048
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer. Breast Cancer Res Treat. 2025 Feb; 209(3):487-492.
PMID: 39625569
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3728-3736.
PMID: 39277671
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.
PMID: 39277672
Effectiveness of the uChicago Health Inequity Classification System on surgical morbidity and mortality conference: A pilot study.
Effectiveness of the uChicago Health Inequity Classification System on surgical morbidity and mortality conference: A pilot study. Am J Surg. 2024 Oct; 236:115834.
PMID: 38991911
The Blue Ribbon Committee II Report and Recommendations on Surgical Education and Training in the United States: 2024.
The Blue Ribbon Committee II Report and Recommendations on Surgical Education and Training in the United States: 2024. Ann Surg. 2024 Oct 01; 280(4):535-546.
PMID: 38814074
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 02 16; 30(4):729-740.
PMID: 38109213
Use of Open Science Practices in Surgical Journals.
Use of Open Science Practices in Surgical Journals. JAMA Surg. 2024 Feb 01; 159(2):228-229.
PMID: 38117492
Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer in the adaptively randomized I-SPY2 trial - Efficacy and biomarker discovery.
Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer in the adaptively randomized I-SPY2 trial - Efficacy and biomarker discovery. Clin Cancer Res. 2023 Dec 18.
PMID: 38109213
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial. Cell Rep Med. 2023 12 19; 4(12):101312.
PMID: 38086377